

## ASX Announcement

### Vale Dr Graham JH Melrose

**Sydney Australia, 14 November 2025:** Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), (**Recce or the Company**) announces with sadness the passing of its founder and inventor of Recce's technology platform, **Dr Graham JH Melrose** BSc (Hons), PhD, MBA, FRACI, CChem and FAICD.

Dr Melrose founded Recce Pharmaceuticals in 2007, drawing upon both his business and scientific expertise as the original inventor of the Company's technology platform. His pioneering work in polymer chemistry and infectious diseases laid the foundation for the RECCE® portfolio of new class anti-infectives and continues to guide the Company's mission and innovation today.

As a recognised pioneer and veteran of the Biotech Industry, Dr Melrose's decades of research and peer reviewed journal articles saw a distinguished career of significant contributions to the fields of Polymer Chemistry, including some eight years as Executive Director and Head of Research at Johnson & Johnson (Asia Pacific).

He held academic positions, including Senior Lecturer in the Department of Applied Organic Chemistry at the University of New South Wales, and served as a visiting research scientist at both Oxford and Munich Universities.

Dr Melrose established Recce with a clear mission: to address the global health threat of antibiotic resistance. Under his leadership, Recce grew from a bold concept into a publicly listed company recognised for its unique anti-infective technologies. After successfully guiding Recce through its formative years delivering >40 granted patents across the largest pharmaceutical markets globally, Dr Melrose retired from the Board in 2021, but remained a dedicated supporter and the Company's largest shareholder.

A Fellow of both the Royal Australian Chemical Institute and the Australian Institute of Company Directors, Dr Melrose's vision, integrity and scientific curiosity inspired all who worked alongside him. His legacy of innovation endures through the next generation of Recce scientists and leaders continuing the work he began.

**James Graham, Chief Executive Officer of Recce Pharmaceuticals, said:**

"Dr Melrose was a remarkable innovator whose scientific vision and passion for solving challenges shaped the very essence of Recce. His legacy endures through the breakthrough



ASX: RCE, FSE: R9Q

Head Office: Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 T +61 (2) 9000 1907

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

technology he created, and through the many people he inspired along the way. We remain deeply grateful for his contribution and determined to continue the mission he began.”

Recce Pharmaceuticals expresses its deepest gratitude for Dr Melrose’s life, leadership and lasting contributions to global health. His contributions to science and innovation will be long remembered and celebrated.

This announcement has been approved for release by Recce Pharmaceuticals Board.

#### Media and Investor Relations

##### Chief Executive Officer

James Graham  
Recce Pharmaceuticals Ltd  
[james.graham@recce.com.au](mailto:james.graham@recce.com.au)

##### Australia

Andrew Geddes  
Seed Media  
[andrew@seedmedia.com.au](mailto:andrew@seedmedia.com.au)

##### USA & Europe

Guillaume van Renterghem  
LifeSci Advisors  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)

## About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

### Media and Investor Relations

#### Chief Executive Officer

James Graham  
Recce Pharmaceuticals Ltd  
[james.graham@recce.com.au](mailto:james.graham@recce.com.au)

#### Australia

Andrew Geddes  
Seed Media  
[andrew@seedmedia.com.au](mailto:andrew@seedmedia.com.au)

#### USA & Europe

Guillaume van Renterghem  
LifeSci Advisors  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)